745.60
-22.25 (-2.90%)
| Previous Close | 767.85 |
| Open | 771.48 |
| Volume | 233,556 |
| Avg. Volume (3M) | 731,991 |
| Market Cap | 78,824,685,568 |
| Price / Earnings (TTM) | 17.98 |
| Price / Earnings (Forward) | 17.73 |
| Price / Sales | 5.78 |
| Price / Book | 2.58 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| TTM Dividend Yield | 0.48% |
| Profit Margin | 31.94% |
| Operating Margin (TTM) | 19.94% |
| Diluted EPS (TTM) | 39.36 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 12.00% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | 3.95 B |
| Levered Free Cash Flow (TTM) | 2.08 B |
| Return on Assets (TTM) | 6.91% |
| Return on Equity (TTM) | 15.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.89% |
| % Held by Institutions | 91.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 975.00 (Guggenheim, 30.77%) | Buy |
| Median | 841.50 (12.86%) | |
| Low | 765.00 (RBC Capital, 2.60%) | Hold |
| Average | 854.00 (14.54%) | |
| Total | 7 Buy, 3 Hold | |
| Avg. Price @ Call | 761.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 923.00 (23.79%) | Buy | 759.86 |
| RBC Capital | 02 Mar 2026 | 765.00 (2.60%) | Hold | 790.81 |
| Guggenheim | 09 Feb 2026 | 975.00 (30.77%) | Buy | 780.28 |
| Cantor Fitzgerald | 02 Feb 2026 | 800.00 (7.30%) | Buy | 755.02 |
| JP Morgan | 02 Feb 2026 | 950.00 (27.41%) | Buy | 755.02 |
| Morgan Stanley | 02 Feb 2026 | 769.00 (3.14%) | Hold | 755.02 |
| Oppenheimer | 02 Feb 2026 | 865.00 (16.01%) | Buy | 755.02 |
| Truist Securities | 02 Feb 2026 | 818.00 (9.71%) | Buy | 755.02 |
| Wells Fargo | 02 Feb 2026 | 800.00 (7.30%) | Hold | 755.02 |
| Evercore ISI Group | 22 Jan 2026 | 875.00 (17.36%) | Buy | 755.51 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RYAN ARTHUR F | - | 777.25 | -100 | -77,725 |
| Aggregate Net Quantity | -100 | |||
| Aggregate Net Value ($) | -77,725 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 777.25 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director | 01 Apr 2026 | Automatic sell (-) | 100 | 777.25 | 77,725 |
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases |
| 30 Jan 2026 | Announcement | Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results |
| 21 Jan 2026 | Announcement | Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search |
| TTM Dividend Yield | 0.48% |
| 1Y Average Dividend Yield | 0.46% |
| Payout Ratio | 2.24% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 20 Feb 2026 | - | 05 Mar 2026 | 0.94 Cash |
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 Cash |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Cash |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Cash |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 0.940 | 1 | 0.13 |
| 2025 | 3.52 | 4 | 0.46 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |